[ad_1]
The new lab, which is expected to begin operations by the end of the year, will be divided into two areas
read more…
In a major development for more effective cancer diagnosis and early detection, a new cutting-edge laboratory will be established in Abu Dhabi to provide patients with advanced molecular genetic, cellular and immunological profiling tests.
Abu Dhabi-based Burjeel Holdings and Canada-based OncoHelix have signed an agreement to deliver personalized medicine and new technologies through a state-of-the-art laboratory capable of meeting the needs of not only UAE hospitals, but the region as a whole.
The new lab, which is expected to begin operations by the end of the year, will be divided into two areas. An advanced diagnostic laboratories segment will focus on providing breakthrough molecular genetic and immunological analytical tests to assist oncologists and physicians in the diagnosis, risk stratification and tailored treat.
The second arm will expand Burjeel Holdings’ existing translational research program to analyze the genomic and immune signatures of cancer patients to develop innovative diagnostics and therapeutics.
Headquartered in Western Canada, OncoHelix has the largest clinically validated cancer comprehensive genomic profiling (CGP) panel in the country. As part of their academic role at the University of Calgary, OncoHelix scientists and clinicians have an impeccable record in translational research, with more than 350 publications in leading scientific journals.
Their translational research team develops impactful precision oncology and immunology pipelines aimed at improving clinical outcomes for cancer patients and transplant recipients.
John Sunil, CEO of Burjeel Holdings, said such collaborations will boost the UAE’s growing medical tourism market and lead it to become a global leader in healthcare.
“Burjeel Holdings continues to invest and form new partnerships to help facilitate the expansion of our translational research programs and improve patient outcomes. This new venture will leverage OncoHelix Inc’s clinical and academic experience to build a state-of-the-art laboratory , we will use the laboratory to provide testing services that are not yet widely available in the UAE.”
Dr. Faisal Khan, OncoHelix CEO and associate professor at the University of Calgary, said the new lab will benefit cancer patients, organ transplant recipients and donors, and patients with autoimmune diseases.
“We are joining forces with Burjeel Holdings to create a local advanced diagnostic program that will not only facilitate early and accurate diagnosis of malignancies and immune system diseases, but also pave the way for newer treatment options guided by disease-specific molecular signatures.
The translational research program will investigate somatic and germline variation in cancer patients and immune signature patterns in transplant recipients and donors in the region to lead the development of precision medicine-based treatments. “
[ad_2]
Source link